Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28123344 | 0.83 | POLB (0.51) | CHRNA7POLB | |
| SCHEMBL16077411 | 0.82 | IAPP (0.45) | IAPPALDH1A1CHRNA7LMNAPOLB | |
| SCHEMBL9984300 | 0.81 | POLB (0.43) | ALDH1A1CHRNA7LMNAPOLB | |
| SCHEMBL16030858 | 0.78 | CYP4F2 (0.53) | ALDH1A1POLB | |
| SCHEMBL26046412 | 0.77 | IAPP (0.70) | IAPPALDH1A1LMNAPRKCI | |
| SCHEMBL1405167 | 0.76 | IAPP (0.50) | IAPPALDH1A1CHRNA7LMNAPOLB | |
| SCHEMBL7761403 | 0.76 | PRKCI (0.47) | ALDH1A1LMNAPOLBPRKCI | |
| SCHEMBL9419249 | 0.76 | KDM4E (0.41) | ALDH1A1POLBPRKCI | |
| SCHEMBL25307580 | 0.76 | IAPP (0.53) | IAPPALDH1A1CHRNA7LMNAPOLB | |
| SCHEMBL26046393 | 0.76 | TYR (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079747-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LTD (GB) | 2011-03-09 | — | — | EP | disclosed |
| EP-2079747-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | Pfizer Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| US-20080161288-A1 | COMPOUNDS | PFIZER INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008044127-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161288-A1 | COMPOUNDS | ADRB2, ADRB1, ADRA2C | IAPP 1485/4885ALDH1A1 295/4885CHRNA7 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.